E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Stable, effort-induced angina pectoris |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10049194 |
E.1.2 | Term | Stable angina pectoris |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to show superiority of PETN over placebo in the treatment of patients with stable, effort-induced angina pectoris receiving anti-anginal background therapy in a modern, regulatory guideline compliant trial. |
|
E.2.2 | Secondary objectives of the trial |
A secondary objective is to evaluate the safety and tolerability of PETN 80 mg bid for treatment of adult subjects with stable, effort-induced angina pectoris. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
At the end of the run-in period the following inclusion criteria must be fulfilled:
1. Second qualifying ETT meeting all of the following criteria:
- Positivity criteria: occurrence of limiting angina and ST-segment depression of at least 1 mm as compared to resting ECG, (horizontal or down sloping and persisting for at least 0.08 seconds after J-point, on at least three consecutive complexes) between 2.5 and 12 minutes of initiation with modified Bruce treadmill ergometer protocol. If the ETT is interrupted before reaching positivity for any reason, the patient will not be included.
- Stability criteria: Difference between selection (Day -7) and inclusion (Day 0) ETT measurements has to be within 20% of the Day 0 value.
2. At least 4 anginal attacks in the 4 week period preceding randomisation
3. Compliance to treatment during the run-in period, i.e. placebo on top of background treatment (calculated compliance at least 85%, in addition, patient should not have missed more than one full daily dose).
|
|
E.4 | Principal exclusion criteria |
Patients will not be included in the trial if one of the following criteria applies:
General exclusion criteria:
1. Incapability of understanding the language in which the information for the patient is given;
2. Presence or history of drug or alcohol abuse;
3. Presence of malignant disease in the past 5 years;
4. The patient is a woman of childbearing potential who does not use a reliable
method of contraception; (Note: A highly effective method of birth control is
defined as those which result in a low failure rate (i.e. less than 1% per year)
when used consistently and correctly such as implants, injectables,
combined oral contraceptives, some IUDs, sexual abstinence or
vasectomised partner);
5. The patient is a pregnant or breast feeding woman;
6. Participation in a concurrent clinical trial or in another trial within the past 4 weeks;
7. Repeated participation in this trial;
8. Anticipated poor medication compliance;
9. The patient is the investigator him/herself.
Trial-specific exclusion criteria:
1. Recent acute myocardial infarction, coronary bypass surgery less than 3 months before inclusion or coronary angioplasty less than 6 months before inclusion;
2. Unstable angina, Prinzmetal angina or microvascular angina;
3. Angina pectoris symptoms typically induced by factors other than physical exertion;
4. Known high-grade left main coronary artery disease that has not been surgically bypassed or mechanically improved;
5. History of untreated, clinical relevant mitral insufficiency, constrictive
pericarditis, pericardial tamponade, severe pulmonary hypertension, aortic
stenosis, hypertrophic obstructive cardiomyopathy or other causes of left
ventricular outflow tract obstruction. If such disorders are treated, the
treatment should be confirmed by echocardiogram not older than 6 months.
The clinical relevance of the disorders is left to the discretion of the
investigator;
6. Hyperresponsitivity or contraindications to nitrovasodilators in particular PETN and nitroglycerin;
7. Anticipated elective percutaneous transluminal coronary angioplasty (PTCA) in the upcoming 12 weeks;
8. Patient who cannot perform exercise tests, in particular for muscular, joint and/or skeletal reasons;
9. Clinically significant heart disease other than coronary artery disease;
10. Congestive heart failure stage III or IV New York heart association (NYHA);
11. Symptomatic hypotension (<100mmHg, dizziness, orthostatic dysregulation);
12. Uncontrolled hypertension (systolic blood pressure at rest at above 180 mmHg or diastolic blood pressure at rest above 100 mmHg);
13. Atrial fibrillation, flutter, pacemaker or cardioverter-defibrillator implantation;
14. ECG abnormalities that would confound ETT interpretation;
15. Repolarisation disturbance seen in the ECG at baseline;
16. Hepatic disorders (alanine aminotransferase [ALT] more than 3 times normal value), renal failure (serum creatinine level above 180 µmol/l);
17. Electrolyte disorders;
18. Anaemia (haemoglobin below 10.0 mg/dl);
19. Thyroid disorders (unless stable and controlled by thyroxin treatment for at least 3 months);
20. Any treatment with unauthorised concomitant medication that could not be interrupted for the duration of the trial;
21. Treatment with amiodarone within 3 months prior to selection;
22. Use of bepridil < 7days before screening
23. Use of digitalis/cardiac glycosides 6 months prior to selection;
24. Inability or lack of consent to wash out long-acting nitrates, calcium channel blockers, trapidil, molsidomine, ranolazine, trimetazidine, nicorandil;
25. Treatment with sildenafil (Viagra®) or other phosphodiesterase-5 inhibitors during trial participation;
26. Severe disease likely to interfere with the trial in the investigator’s judgement;
27. Known carrier of Hepatitis B (HBs) antigen, human immunodeficiency virus (HIV) or Hepatitis C virus (HCV) antibodies;
28. History of severe psychiatric or behavioural disorders likely to interfere with the trial;
29. History of serious abnormal drug reaction;
30. Use of investigational drug within 30 days of pre-selection, or concurrent therapy with an investigational drug(s).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy:
Change in Total Exercise Duration (TED) [seconds]) from baseline after 12 weeks of treatment with PETN 80 mg bid as compared to placebo bid assessed in the trough between the morning and the midday dose, (i.e. at 5 h after intake of morning dose of study medication).
Secondary efficacy:
- Angina attack frequency, intensity, and duration (according to patient diary);
- Change in time to onset of anginal pain on ETT after 6 and 12 weeks of treatment;
- Change in exercise capacity (METs) after 6 and 12 weeks of treatment
- Concomitant use of short-acting nitrates (according to patient diary)
- Change in time to limiting angina (TLA, seconds) during ETT after 6 and 12 weeks of treatment
- Change in TED (seconds) during ETT after 6 weeks of treatment
- Change in time to 1 mm ST segment depression (TST) (horizontal or down-sloping for more than 0.08 s after the J point) after 6 and 12 weeks of treatment;
- Angina attack intensity, and duration (according to patient diary);
- Change in Health related quality of life scores after 12 weeks of treatment;
- Borg scale.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 39 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 55 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of last subject, estimated March 2012. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |